

REFERENSI

- Abramson, D. H., Beaverson, K., Sangani, P., Vora, R. A., Lee, T. C., Hochberg, H. M., Kirsztrot, J. & Ranjithan, M. 2003. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. *Pediatrics*, 112, 1248-1255.
- Abramson, D. H., Dunkel, I. J., Brodie, S. E., Kim, J. W. & Gobin, Y. P. 2008. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. *Ophthalmology*, 115, 1398-1404. e1.
- Abramson, D. H. & Scheffler, A. C. 2004. Update on retinoblastoma. *Retina*, 24, 828-848.
- Aerts, I., Rouic, L.-L., Gauthier-Villars, M., Brisse, H., Doz, F. & Desjardins, L. 2006. Retinoblastoma. *Orphanet J. Rare Dis.*, 1, 1-11.
- Aghajani, M. J., Roberts, T. L., Yang, T., Mccafferty, C. E., Caixeiro, N. J., Desouza, P. & Niles, N. 2019. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. *Endocrine connections*, 8, 1040-1051.
- Al-Nawaiseh, I., Jammal, H. M., Khader, Y. S., Jaradat, I. & Barham, R. 2014. Retinoblastoma in Jordan, 2003–2013: ocular survival and associated factors. *Ophthalmic Epidemiol.*, 21, 406-411.
- Alsaab, H. O., Sau, S., Alzharni, R., Tatiparti, K., Bhise, K., Kashaw, S. K. & Iyer, A. K. 2017. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front. Pharmacol.*, 8, 561.
- Andreoli, M. T., Chau, F. Y., Shapiro, M. J. & Leiderman, Y. I. 2017. Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry. *Can. J. Ophthalmol.*, 52, 592-598.
- Anisman, H., Hayley, S. & Kusnecov, A. W. 2018. *The immune system and mental health*, Academic Press.
- Areán, C., Orellana, M. E., Abourbih, D., Abreu, C., Pifano, I. & Burnier, M. N. J. a. O. O. 2010. Expression of vascular endothelial growth factor in retinoblastoma. 128, 223-229.
- Atchaneeyasakul, L.-O., Wongsiwaroj, C., Uprasertkul, M., Sanpakit, K., Thephamongkhon, K. & Trinavarat, A. J. J. O. O. 2009. Prognostic factors and treatment outcomes of retinoblastoma in pediatric patients: a single-institution study. 53, 35-39.
- Bartel, D. P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*, 116, 281-297.
- Bedard, P. L., Hansen, A. R., Ratain, M. J. & Siu, L. L. 2013. Tumour heterogeneity in the clinic. *Nature*, 501, 355-364.
- Berry, J. L., Xu, L., Murphree, A. L., Krishnan, S., Stachelek, K., Zolfaghari, E., McGovern, K., Lee, T. C., Carlsson, A. & Kuhn, P. J. J. O. 2017. Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. 135, 1221-1230.
- Berry, J. L., Xu, L., Polski, A., Jubran, R., Kuhn, P., Kim, J. W. & Hicks, J. 2020. Aqueous humor is superior to blood as a liquid biopsy for retinoblastoma. *Ophthalmology*, 127, 552-554.
- Brantley, J., Milam A & Harbour, J. W. 2001. The molecular biology of retinoblastoma. *Ocul. Immunol. Inflamm.*, 9, 1-8.
- Broadus, E., Topham, A. & Singh, A. D. 2009. Survival with retinoblastoma in the USA: 1975–2004. *Br. J. Ophthalmol.*, 93, 24-27.
- Buccitelli, C. & Selbach, M. 2020. mRNAs, proteins and the emerging principles of gene expression control. *Nat. Rev. Genet.*, 21, 630-644.
- Chang, C.-Y., Chiou, T.-J., Hwang, B., Bai, L.-Y., Hsu, W.-M. & Hsieh, Y.-L. J. J. J. O. O. 2006. Retinoblastoma in Taiwan: survival rate and prognostic factors. 50, 242-249.
- Chawla, B., Kumar, K. & Singh, A. D. 2017. Influence of socioeconomic and cultural factors on retinoblastoma management. *Asia-Pacific journal of oncology nursing*, 4, 187.
- Chen, D. S. & Mellman, I. J. I. 2013. Oncology meets immunology: the cancer-immunity cycle. 39, 1-10.
- Chen, L. & Han, X. 2015. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. *J. Clin. Invest.*, 125, 3384-3391.
- Chen, M., Jiang, H., Zhang, J., Shen, G., Jiang, Y., Li, H. & Liu, Z. 2017. Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study. *Acta Ophthalmol. (Copenh.)*, 95, 613-618.
- Chen, Y., Lin, H., Hsu, W., Lee, S. & Cheng, C. 2010. Retinoblastoma in Taiwan: incidence and survival characteristics from 1979 to 2003. *Eye*, 24, 318-322.



- Chen, Y.-M. 2017. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. *J. Chin. Med. Assoc.*, 80, 7-14.
- Chuluunbat, T., Jamiyanjav, B., Munkhuu, B., Bazarsad, U., Molom, A., Kao, L.-Y. & Wu, W.-C. 2016. Retinoblastoma in Mongolia: Clinical characteristics and survival from 1987 to 2014. *Taiwan journal of ophthalmology*, 6, 79-84.
- Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R. & Poletti, A. J. C. 2011. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. 147, 759-772.
- Cuylen, S., Blaukopf, C., Politi, A. Z., Müller-Reichert, T., Neumann, B., Poser, I., Ellenberg, J., Hyman, A. A. & Gerlich, D. W. 2016. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. *Nature*, 535, 308-312.
- Darvin, P., Toor, S. M., Sasidharan Nair, V., Elkord, E. J. E. & Medicine, M. 2018. Immune checkpoint inhibitors: recent progress and potential biomarkers. 50, 1-11.
- De Jong, M. C., Kors, W. A., De Graaf, P., Castelijns, J. A., Kivelä, T. & Moll, A. C. 2014. Trilateral retinoblastoma: a systematic review and meta-analysis. *The lancet oncology*, 15, 1157-1167.
- De Oliveira Reis, A. H., De Carvalho, I. N. S. R., De Sousa Damasceno, P. B., Ferman, S. E., Lucena, E., Lopez-Camelo, J. S., Seuánez, H. N. & Vargas, F. R. 2012. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. *Pediatr. Blood Cancer*, 59, 39-43.
- Delsin, L. E. A., Salomao, K. B., Pezuk, J. A., Brasseco, M. S. J. J. O. C. R. & Oncology, C. 2019. Expression profiles and prognostic value of miRNAs in retinoblastoma. 145, 1-10.
- Dharmawidari, D., Prijanto, H. D. S. & Hendrian, D. 2010. Ocular Survival Rate Penderita Retinoblastoma yang Telah Dilakukan E nukleasi atau Eksenterasi di RSUD Dr. Soetomo Surabaya. *Journal Oftalmologi Indonesia*, 7, 94-102.
- Dimaras, H. & Corson, T. W. 2019. Retinoblastoma, the visible CNS tumor: a review. *J. Neurosci. Res.*, 97, 29-44.
- Dimaras, H., Corson, T. W., Cobrinik, D., White, A., Zhao, J., Munier, F. L., Abramson, D. H., Shields, C. L., Chantada, G. L. & Njuguna, F. 2015. Retinoblastoma. *Nature Reviews Disease Primers*, 1, 15021.
- Dimaras, H., Khetan, V., Halliday, W., Orlic, M., Prigoda, N. L., Piovesan, B., Marrano, P., Corson, T. W., Eagle Jr, R. C. & Squire, J. A. 2008. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. *Hum. Mol. Genet.*, 17, 1363-1372.
- Dimaras, H., Kimani, K., Dimba, E. A., Gronsdahl, P., White, A., Chan, H. S. & Gallie, B. L. 2012. Retinoblastoma. *The Lancet*, 379, 1436-1446.
- Dommering, C. J., Marees, T., Van Der Hout, A. H., Imhof, S. M., Meijers-Heijboer, H., Ringens, P. J., Van Leeuwen, F. E. & Moll, A. C. 2012. RB1 mutations and second primary malignancies after hereditary retinoblastoma. *Fam. Cancer*, 11, 225-233.
- Draper, G., Sanders, B., Brownbill, P. & Hawkins, M. J. B. J. O. C. 1992. Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. 66, 211-219.
- Estephan, R., Kil, S. H., Rosen, S. T. & Querfeld, C. 2018. PD-L1 Expression Is Regulated By microRNAs-21 and -130 in Cutaneous T-Cell Lymphoma. *Blood*, 132, 4108-4108.
- Fabian, I. D., Onadim, Z., Karaa, E., Duncan, C., Chowdhury, T., Scheimberg, I., Ohnuma, S.-I., Reddy, M. A. & Sagoo, M. S. 2018. The management of retinoblastoma. *Oncogene*, 37, 1551-1560.
- Feng, J., Ren, P., Gou, J., Li, Z. J. O. & Therapy 2016. Prognostic significance of TAZ expression in various cancers: a meta-analysis. 9, 5235.
- Feng, J., Yang, H., Zhang, Y., Wei, H., Zhu, Z., Zhu, B., Yang, M., Cao, W., Wang, L. & Wu, Z. 2017. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. *Oncogene*, 36, 5829-5839.
- Finger, P., Harbour, J., Murphree, A., Karciglu, Z., Seregard, S., Albert, D., Augsburger, J., Chevez-Barrios, P., Coupland, S. & Eagle, R. 2010. Retinoblastoma. *AJCC cancer staging manual*, 7, 561-56.
- Finger, P. T., Harbour, J. W. & Karciglu, Z. A. 2002. Risk factors for metastasis in retinoblastoma. *Surv. Ophthalmol.*, 47, 1-16.
- Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M. & Dryja, T. P. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature*, 323, 643-646.
- Gao, J., Zeng, J., Guo, B., He, W., Chen, J., Lu, F. & Chen, D. 2016. Clinical presentation and treatment outcome of retinoblastoma in children of South Western China. *Medicine*, 95.



- Gauvin, C., Krishnan, V., Kaci, I., Tran-Thanh, D., Bédard, K., Albadine, R., Leduc, C., Gaboury, L., Blais, N. & Tehfe, M. 2021. Survival impact of aggressive treatment and PD-L1 expression in oligometastatic NSCLC. *Current Oncology*, 28, 593-605.
- Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A. & Tarpey, P. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N. Engl. J. Med.*, 366, 883-892.
- Ghose, S., Seth, V., Singhal, V., Sood, N. & Dayal, Y. 1983. Diagnostic problems in leucocoria. *Indian J. Ophthalmol.*, 31, 233.
- Gichigo, E. N., Kariuki-Wanyoike, M. M., Kimani, K. & Nentwich, M. M. 2015. Retinoblastoma in Kenya: survival and prognostic factors. *Ophthalmology*, 112, 255-60.
- Goolam, S., Kana, H., Welsh, N., Wainwright, L., Poole, J. & Mayet, I. 2018. A 20-year retrospective review of retinoblastoma at two tertiary academic hospitals in Johannesburg, South Africa. *Ocular oncology and pathology*, 4, 170-175.
- Goss, D. & Domashevskiy, A. 2016. Messenger RNA (mRNA): The link between DNA and protein.
- Guo, X., Zhao, Y., Yan, H., Yang, Y., Shen, S., Dai, X., Ji, X., Ji, F., Gong, X.-G. & Li, L. 2017. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. *Genes Dev.*, 31, 247-259.
- Han, Y., Liu, D. & Li, L. 2021. Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer. *Cancer Cell Int.*, 21, 1-14.
- Hanahan, D. 2022. Hallmarks of cancer: new dimensions. *Cancer Discov.*, 12, 31-46.
- Hansen, C. G., Morioishi, T. & Guan, K.-L. J. T. I. C. B. 2015. YAP and TAZ: a nexus for Hippo signaling and beyond. 25, 499-513.
- Hao, F., Mou, Y., Zhang, L., Wang, S. & Yang, Y. J. B. R. 2018. LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma. 38.
- Harrington, K. J. 2016. Chemotherapy and targeted agents. *Maxillofacial Surgery*, 339-354.
- He, X. & Xu, C. 2020. Immune checkpoint signaling and cancer immunotherapy. *Cell Res.*, 30, 660-669.
- Hermanek, P., Gospodarowicz, M. K., Henson, D. E., Hutter, R. V. & Sobin, L. H. 2012. *Prognostic factors in cancer*, Springer Science & Business Media.
- Hiasat, J. G., Saleh, A., Al-Hussaini, M., Al Nawaiseh, I., Mehryar, M., Qandeel, M., Mohammad, M., Deebajah, R., Sultan, I. & Jaradat, I. 2019. The predictive value of magnetic resonance imaging of retinoblastoma for the likelihood of high-risk pathologic features. *European journal of ophthalmology*, 29, 262-268.
- Houston, S. K., Murray, T. G., Wolfe, S. Q. & Fernandes, C. E. 2011. Current update on retinoblastoma. *Int. Ophthalmol. Clin.*, 51, 77.
- Howell, M. & Shepherd, M. 2021. The immune system. *Anaesthesia & Intensive Care Medicine*, 22, 518-521.
- Ilić, M. & Hofman, P. 2016. Pros: Can tissue biopsy be replaced by liquid biopsy? *Translational lung cancer research*, 5, 420.
- Jain, E., Sharma, S., Aggarwal, A., Bhardwaj, N., Dewan, A., Kumar, A., Jain, D., Bhattacharya, M., Saurav, G. K. & Kini, L. 2021. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective. *Pathology-Research and Practice*, 228, 153497.
- Janse Van Rensburg, H. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., Minassian, L. M., Graham, C. H., Rauh, M. J. & Yang, X. 2018. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1 TAZ Regulates Cancer Immune Evasion through PD-L1. *Cancer Res.*, 78, 1457-1470.
- Jia, L., Zhang, Q. & Zhang, R. 2018. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. *Cancer biology & medicine*, 15, 116.
- Kaliki, S., Ji, X., Zou, Y., Rashid, R., Sultana, S., Taju Sherief, S., Cassoux, N., Y Diaz Coronado, R., Luis Garcia Leon, J. & López, A. M. Z. 2021. Lag time between onset of first symptom and treatment of retinoblastoma: an international collaborative study of 692 patients from 10 countries. *Cancers (Basel)*, 13, 1956.
- Kao, L.-Y., Su, W.-W. & Lin, Y.-W. 2002. Retinoblastoma in Taiwan: survival and clinical characteristics 1978–2000. *Jpn. J. Ophthalmol.*, 46, 577-580.
- Karachaliou, N., Cao, M. G., Teixidó, C., Viteri, S., Morales-Espinosa, D., Santarpia, M. & Rosell, R. 2015. Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. *Cancer biology & medicine*, 12, 79.



- Khosravi, A., Shahrabi, S., Shahjahani, M. & Saki, N. 2015. The bone marrow metastasis niche in retinoblastoma. *Cell. Oncol.*, 38, 253-263.
- Knudson, A. G. 2001. Two genetic hits (more or less) to cancer. *Nat. Rev. Cancer*, 1, 157-162.
- Kodrat, H. & Gondhowiardjo, S. A. 2013. Radioterapi pada Retinoblastoma. *Radioterapi & Onkologi Indonesia*, 4.
- L Garner, A. & D Janda, K. 2011. Protein-protein interactions and cancer: targeting the central dogma. *Curr. Top. Med. Chem.*, 11, 258-280.
- Lai, D., Ho, K. C., Hao, Y. & Yang, X. J. C. R. 2011. Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional Targets Cyr61 and CTGFCyr61/CTGF Mediate TAZ-induced Taxol Resistance. 71, 2728-2738.
- Lee, B. S., Park, D. I., Lee, D. H., Lee, J. E., Yeo, M.-K., Park, Y. H., Lim, D. S., Choi, W., Yoo, G. & Kim, H.-B. 2017. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. *Biochem. Biophys. Res. Commun.*, 491, 493-499.
- Lei, Q.-Y., Zhang, H., Zhao, B., Zha, Z.-Y., Bai, F., Pei, X.-H., Zhao, S., Xiong, Y. & Guan, K.-L. 2008. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. *Mol. Cell. Biol.*, 28, 2426-2436.
- Li, S.-Y., Chen, S. C.-C., Tsai, C.-F., Sheu, S.-M., Yeh, J.-J. & Tsai, C.-B. 2016. Incidence and survival of retinoblastoma in Taiwan: a nationwide population-based study 1998–2011. *Br. J. Ophthalmol.*, 100, 839-842.
- Lu, X., Tu, H., Tang, D., Huang, X. & Sun, F. 2022. miR-130a-3p enhances the chemosensitivity of Y79 retinoblastoma cells to vincristine by targeting PAX6 expression. *Curr. Eye Res.*, 47, 418-425.
- Luo, X., Ye, H., Ding, Y.-G., Du, Y. & Yang, H. J. T. J. O. M. S. 2015. Clinical characteristics and prognosis of patients with retinoblastoma: 8-year follow-up. 45, 1256-1262.
- Lussier, D. M., O'neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P. & Blattman, J. N. 2015. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. *Journal of immunotherapy (Hagerstown, Md.: 1997)*, 38, 96.
- Ma, W., Gilligan, B. M., Yuan, J. & Li, T. 2016. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. *J. Hematol. Oncol. J Hematol Oncol*, 9, 1-21.
- Maccarthy, A., Bayne, A., Brownbill, P., Bunch, K., Diggens, N., Draper, G., Hawkins, M., Jenkinson, H., Kingston, J. & Stiller, C. 2013. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004. *Br. J. Cancer*, 108, 2455-2463.
- Maccarthy, A., Birch, J., Draper, G., Hungerford, J., Kingston, J., Kroll, M., Stiller, C., Vincent, T. & Murphy, M. 2009. Retinoblastoma: treatment and survival in Great Britain 1963 to 2002. *Br. J. Ophthalmol.*, 93, 38-39.
- Maccarthy, A., Draper, G., Steliarova-Foucher, E. & Kingston, J. 2006. Retinoblastoma incidence and survival in European children (1978–1997). Report from the Automated Childhood Cancer Information System project. *Eur. J. Cancer*, 42, 2092-2102.
- Macfarlane, L.-A. & R Murphy, P. 2010. MicroRNA: biogenesis, function and role in cancer. *Curr. Genomics*, 11, 537-561.
- Mahmoudi, M. 2009. *Immunology Made Ridiculously Simple*, Medmaster Miami, FL.
- Mallipatna, A., Marino, M. & Singh, A. D. 2016. Genetics of retinoblastoma. *The Asia-Pacific Journal of Ophthalmology*, 5, 260-264.
- Maugeri-Saccà, M. & De Maria, R. 2018. The Hippo pathway in normal development and cancer. *Pharmacol. Ther.*, 186, 60-72.
- Mcdermott, D. F. & Atkins, M. B. 2013. PD-1 as a potential target in cancer therapy. *Cancer medicine*, 2, 662-673.
- Menon, S. S., Guruvayoorappan, C., Sakthivel, K. M. & Rasmi, R. R. 2019. Ki-67 protein as a tumour proliferation marker. *Clin. Chim. Acta*, 491, 39-45.
- Mesnage, S., Auguste, A., Genestie, C., Dunant, A., Pain, E., Drusch, F., Gouy, S., Morice, P., Bentivegna, E. & Lhomme, C. 2017. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). *Ann. Oncol.*, 28, 651-657.
- Moroishi, T., Hayashi, T., Pan, W.-W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A. & Guan, K.-L. 2016. The Hippo pathway kinases LATS1/2 suppress cancer immunity. *Cell*, 167, 1525-1539. e17.
- Moticka 2016. Activation of T Lymphocytes and MHC Restriction. *A Historical Perspective on Evidence-Based Immunology*. Elsevier.



- Murphree, A. L. 2005. Intraocular retinoblastoma: the case for a new group classification. *Ophthalmology clinics of north america*, 18, 41-viii.
- Natliani, F., Sundari, S. & Ekantini, R. 2011. Agreement between ultrasonography and histopatologic findings in diagnosing retinoblastoma. *J. Med. Sci.*, 43, 8-11.
- Nyaywa, M., Chipalo-Mutati, G. & Chintu, C. 2016. Modes of presentation, management and outcome of retinoblastoma treatment at university teaching hospital. *Med. J. Zambia*, 43, 216-223.
- Ortiz, M. V. & Dunkel, I. J. 2016. Retinoblastoma. *J. Child Neurol.*, 31, 227-236.
- Pelissier, F. A., Garbe, J. C., Ananthanarayanan, B., Miyano, M., Lin, C., Jokela, T., Kumar, S., Stampfer, M. R., Lorens, J. B. & Labarge, M. a. J. C. R. 2014. Age-related dysfunction in mechanotransduction impairs differentiation of human mammary epithelial progenitors. 7, 1926-1939.
- Prasad Sah, K., Saiju, R., Roy, P. & Kafle, S. 2013. Retinoblastoma: ten years experience at Kanti Children's Hospital. *Journal of the Nepal Medical Association*, 52.
- Rahman, A. 2015. Dilema dalam manajemen retinoblastoma. *Majalah Kedokteran Andalas*, 37, 101-106.
- Ramasubramanian, A. & Shields, C. L. 2012. *Retinoblastoma*, JP Medical Ltd.
- Ramjee, V., Li, D., Manderfield, L. J., Liu, F., Engleka, K. A., Aghajanian, H., Rodell, C. B., Lu, W., Ho, V. & Wang, T. 2017. Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarction. *J. Clin. Invest.*, 127, 899-911.
- Rao, R. & Honavar, S. G. 2017. Retinoblastoma. *The Indian Journal of Pediatrics*, 84, 937-944.
- Reese, A. & Ellsworth, R. 1963. The evaluation and current concept of retinoblastoma therapy. *Transactions-American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology*, 67, 164-172.
- Reszec, J., Sulkowska, M., Koda, M., Kanczuga-Koda, L. & Sulkowski, S. 2004. Expression of cell proliferation and apoptosis markers in papillomas and cancers of conjunctiva and eyelid. *Ann. N. Y. Acad. Sci.*, 1030, 419-426.
- Roberts, D., Duggan-Keen, M., Aherne, G. & Long, D. J. B. J. O. O. 1986. Immunogenetic studies in retinoblastoma. 70, 686-691.
- Rodriguez-Galindo, C., Wilson, M. W., Chantada, G., Fu, L., Qaddoumi, I., Antoneli, C. L., Leal-Leal, C., Sharma, T., Barnoya, M. & Epelman, S. 2008. Retinoblastoma: one world, one vision. *Pediatrics*, 122, e763-e770.
- Rosdiana, N. 2016. Gambaran Klinis dan Laboratorium Retinoblastoma. *Sari Pediatri*, 12, 319-22.
- Schedler, K. J., Traine, P. G., Lohmann, D. R., Haritoglou, C., Metz, K. A. & Rodrigues, E. B. 2016. Hereditary diffuse infiltrating retinoblastoma. *Ophthalmic Genet.*, 37, 95-97.
- Schlüter, C., Duchrow, M., Wohlenberg, C., Becker, M., Key, G., Flad, H.-D. & Gerdes, J. 1993. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. *The Journal of cell biology*, 123, 513-522.
- Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P. & Beras, A. 2020. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. *Ann. Oncol.*, 31, 599-608.
- Scholzen, T. & Gerdes, J. 2000. The Ki-67 protein: from the known and the unknown. *J. Cell. Physiol.*, 182, 311-322.
- Sebio, A., Matsusaka, S., Zhang, W., Yang, D., Ning, Y., Stremtizer, S., Stintzing, S., Sunakawa, Y., Yamauchi, S. & Fujimoto, Y. J. T. P. J. 2016. Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. 16, 312-319.
- Shadbad, M. A., Asadzadeh, Z., Derakhshani, A., Hosseinkhani, N., Mokhtarzadeh, A., Baghbanzadeh, A., Hajiasgharzadeh, K., Brunetti, O., Argentiero, A. & Racanelli, V. 2021. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery. *Biomed. Pharmacother.*, 143, 112213.
- Shi, J.-X., Qin, J.-J., Ye, H., Wang, P., Wang, K.-J. & Zhang, J.-Y. J. E. R. O. M. D. 2015. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis. 15, 829-852.
- Shields, C. L., Mashayekhi, A., Au, A. K., Czyz, C., Leahey, A., Meadows, A. T. & Shields, J. A. 2006. The International Classification of Retinoblastoma predicts chemoreduction success. *Ophthalmology*, 113, 2276-2280.
- Shields, C. L. & Shields, J. A. 2004. Diagnosis and management of retinoblastoma. *Cancer Control*, 11, 317-327.



- Sinambela, A. & Djakaria, H. 2017. Peran Radiasi dalam Tatalaksana Retinoblastoma. *Radioterapi & Onkologi Indonesia*, 8, 77-83.
- Singh, L. & Kashyap, S. J. I. J. O. O. 2018. Update on pathology of retinoblastoma. 11, 2011.
- Singh, L., Singh, M. K., Rizvi, M. A., Bakhshi, S., Meel, R., Lomi, N., Sen, S. & Kashyap, S. 2020. Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma. *Cancer Immunol. Immunother.*, 69, 1087-1099.
- Sobecki, M., Mrouj, K., Camasses, A., Parisi, N., Nicolas, E., Llères, D., Gerbe, F., Prieto, S., Krasinska, L. & David, A. 2016. The cell proliferation antigen Ki-67 organises heterochromatin. *elife*, 5, e13722.
- Soebagjo, H. D., Bintoro, U. Y. & Soemitro, S. B. 2019. Evaluation of KI-67, Apoptosis, and Hyaluronic Acid in Grading Retinoblastoma. *Folia Medica Indonesiana*, 55, 206-212.
- Soliman, S. E., Dimaras, H., Khetan, V., Gardiner, J. A., Chan, H. S., Héon, E. & Gallie, B. L. 2016. Prenatal versus postnatal screening for familial retinoblastoma. *Ophthalmology*, 123, 2610-2617.
- Sun, J., Wang, J., Pefanis, E., Chao, J., Rothschild, G., Tachibana, I., Chen, J. K., Ivanov, I. I., Rabadan, R. & Takeda, Y. 2015. Transcriptomics identify CD9 as a marker of murine IL-10-competent regulatory B cells. *Cell Rep.*, 13, 1110-1117.
- Sun, X. & Kaufman, P. D. 2018. Ki-67: more than a proliferation marker. *Chromosoma*, 127, 175-186.
- Taha, Z., J. Janse Van Rensburg, H. & Yang, X. 2018. The Hippo pathway: immunity and cancer. *Cancers (Basel)*, 10, 94.
- Tomar, A. S., Finger, P. T., Gallie, B., Kivelä, T. T., Mallipatna, A., Zhang, C., Zhao, J., Wilson, M. W., Brennan, R. C. & Burges, M. 2022. High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma: A Multicenter, International Data-Sharing American Joint Committee on Cancer Study. *Ophthalmology*.
- Topilow, N. J., Tran, A. Q., Koo, E. B. & Alabiad, C. R. 2020. Etiologies of Proptosis: A review. *Internal medicine review (Washington, DC: Online)*, 6.
- Truong, B., Green, A. L., Friedrich, P., Ribeiro, K. B. & Rodriguez-Galindo, C. 2015. Ethnic, racial, and socioeconomic disparities in retinoblastoma. *JAMA pediatrics*, 169, 1096-1104.
- Tuminello, S., Sikavi, D., Veluswamy, R., Gamarra, C., Lieberman-Cribbin, W., Flores, R. & Taioli, E. 2020. PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis. *Translational lung cancer research*, 9, 1343.
- Tuncer, S., Sencer, S., Kebudi, R., Tanyıldız, B., Cebeci, Z. & Aydın, K. 2016. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: first 4-year experience from a single institution in Turkey. *Acta Ophthalmol. (Copenh.)*, 94, e644-e651.
- Tung, J.-N., Lin, P.-L., Wang, Y.-C., Wu, D.-W., Chen, C.-Y. & Lee, H. 2018. PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression. *Oncotarget*, 9, 4637.
- Varelas, X., Sakuma, R., Samavarchi-Tehrani, P., Peerani, R., Rao, B. M., Dembowy, J., Yaffe, M. B., Zandstra, P. W. & Wrana, J. L. J. N. C. B. 2008. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. 10, 837-848.
- Vici, P., Mottolese, M., Pizzuti, L., Barba, M., Sperati, F., Terrenato, I., Di Benedetto, A., Natoli, C., Gamucci, T. & Angelucci, D. 2014. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. *Oncotarget*, 5, 9619.
- Vitarani, C. M. 2019. *Hubungan Antara Usia Saat Diagnosis dan Interval Keterlambatan Diagnosis dengan Stadium Penyakit Retinoblastoma di RSUP Dr. Sardjito*. Undergraduate cross sectional, Universitas Gadjah Mada.
- Waddell, K. M., Kagame, K., Ndamira, A., Twinamasiko, A., Picton, S. V., Simmons, I. G., Johnston, W. T. & Newton, R. 2015. Clinical features and survival among children with retinoblastoma in Uganda. *Br. J. Ophthalmol.*, 99, 387-390.
- Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J. & Cao, K. 2017. Role of tumor microenvironment in tumorigenesis. *J. Cancer*, 8, 761.
- Wang, Y., Dong, T., Xuan, Q., Zhao, H., Qin, L. & Zhang, Q. 2018. Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer. *J. Breast Cancer*, 21, 124-133.
- Wang, Y.-Z., Zhang, Y., Huang, D.-S., Shi, J.-T., Ma, J.-M., Li, B., Xu, X.-L., Zhou, Y. & Gu, H.-L. 2021. Clinical characteristics, treatment and prognosis of children with unilateral retinoblastoma and intracranial segment of Retrobulbar optic nerve invasion. *BMC Ophthalmol.*, 21, 1-8.



- Wegler, C., Ölander, M., Wiśniewski, J. R., Lundquist, P., Zettl, K., Åsberg, A., Hjelmæsæth, J., Andersson, T. B. & Artursson, P. 2020. Global variability analysis of mRNA and protein concentrations across and within human tissues. *NAR genomics and bioinformatics*, 2, lqz010.
- White, S. M., Murakami, S. & Yi, C. 2019. The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity. *Oncogene*, 38, 2899-2909.
- Who 2014. Review of Cancer Medicines on the WHO List of Essential Medicines. *Union for International Cancer Control*.
- Wong, E. S., Choy, R. W., Zhang, Y., Chu, W. K., Chen, L. J., Pang, C. P. & Yam, J. C. 2022. Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors. *The Lancet Global Health*.
- Wong, E. Y., Xu, L., Shen, L., Kim, M. E., Polski, A., Prabakar, R. K., Shah, R., Jubran, R., Kim, J. W. & Biegel, J. A. 2021. Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy. *NPJ Precision Oncology*, 5, 1-6.
- Wongmas, P., Jetsrisuparb, A., Komvilaisak, P., Suwanrungruang, K., Choeprasert, W., Sriplung, H. & Wiangnon, S. 2015. Incidences, trends and long term outcomes of retinoblastoma in three cancer registries, Thailand. *Asian Pac. J. Cancer Prev.*, 16, 6899-6902.
- Wu, C.-E., Chang, C.-F., Kou-Sheng, L., Chiang, J., Lee, S.-W. & Chiu, Y.-C. 2020. PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC. *Analytical Cellular Pathology*, 2020.
- Wu, Y., Chen, W., Xu, Z. P. & Gu, W. 2019. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. *Front. Immunol.*, 10, 2022.
- Xie, H., Wu, L., Deng, Z., Huo, Y. & Cheng, Y. 2018a. Emerging roles of YAP/TAZ in lung physiology and diseases. *Life Sci.*, 214, 176-183.
- Xie, W.-B., Liang, L.-H., Wu, K.-G., Wang, L.-X., He, X., Song, C., Wang, Y.-Q. & Li, Y.-H. 2018b. MiR-140 expression regulates cell proliferation and targets PD-L1 in NSCLC. *Cell. Physiol. Biochem.*, 46, 654-663.
- Yahaya, J. 2018. The role of Ki-67 immunoexpression in predicting the biological behavior of retinoblastoma tumor in Tanzania. *Am. J. Clin. Pathol.*, 150, S37.
- Yamauchi, T. & Moroishi, T. 2019. Hippo Pathway in Mammalian Adaptive Immune System. *Cells*, 8.
- Yannuzzi, N. A., Francis, J. H., Marr, B. P., Belinsky, I., Dunkel, I. J., Gobin, Y. P. & Abramson, D. H. 2015. Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis. *JAMA Ophthalmol*, 133, 1062-6.
- Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. & Seiwert, T. Y. J. C. C. R. 2017. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. 23, 3158-3167.
- Yu, C.-L., Tucker, M. A., Abramson, D. H., Furukawa, K., Seddon, J. M., Stovall, M., Fraumeni Jr, J. F. & Kleinerman, R. A. 2009. Cause-specific mortality in long-term survivors of retinoblastoma. *J. Natl. Cancer Inst.*, 101, 581-591.
- Yun, J., Li, Y., Xu, C.-T. & Pan, B.-R. 2011. Epidemiology and Rb1 gene of retinoblastoma. *International Journal of Ophthalmology*, 4, 103.
- Zanconato, F., Cordenonsi, M. & Piccolo, S. 2016. YAP/TAZ at the roots of cancer. *Cancer Cell*, 29, 783-803.
- Zhang, A., Wang, X., Fan, C. & Mao, X. 2021. The Role of ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer. *Front. Endocrinol. (Lausanne)*, 12.
- Zhang, B., Song, Y., Fu, Y., Zhu, B., Wang, B. & Wang, J. 2020. Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China. *BMC Cancer*, 20, 86.
- Zhang, J., Schweers, B. & Dyer, M. A. 2004. The first knockout mouse model of retinoblastoma. *Cell Cycle*, 3, 950-957.
- Zhang, Y., Wu, D., Xia, F., Xian, H., Zhu, X., Cui, H. & Huang, Z. 2016. Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma. *Biochem. Biophys. Res. Commun.*, 473, 600-606.
- Zhang, Y., Xue, C., Cui, H. & Huang, Z. 2015. High expression of TAZ indicates a poor prognosis in retinoblastoma. *Diagn. Pathol.*, 10, 1-9.
- Zhou, X. & Lei, Q.-Y. 2016. Regulation of TAZ in cancer. *Protein Cell*, 7, 548-561.
- Zhu, J. Y., Lin, S. & Ye, J. 2019. YAP and TAZ, the conductors that orchestrate eye development, homeostasis, and disease. *J. Cell. Physiol.*, 234, 246-258.